Showing 921-930 of 1478 results for "".
- Industry Veteran Ann Deren-Lewis Joins Mindera as Chief Commercial Officerhttps://practicaldermatology.com/news/industry-veteran-ann-deren-lewis-joins-mindera-as-chief-commercial-officer/2460879/Ann Deren-Lewis is Mindera’s new Chief Commercial Officer. She most recently served as Sr. Vice President of Corporate Development at Zerigo Health (formerly Clarify Medical) where she led commercial operations, including sales, marketing, medical affairs, and the clinical c
- ParaPRO’s Natroba for Scabies Now Availablehttps://practicaldermatology.com/news/parapros-natroba-for-scabies-now-available/2460877/ParaPRO’s Natroba (spinosad) Topical Suspension, 0.9% for scabies is now available. Natroba is the first new scabies drug to be approved by the U.S. Food and Drug Administration (FDA) in more than 30 years. Earlier this year, the company received FDA approval of its supp
- Hot Off the Press: Dr. Brooke Jackson’s New Book “Skin Care for Runners” Now Availablehttps://practicaldermatology.com/news/hot-off-the-press-dr-brooke-jacksons-new-book-skin-care-for-runners-now-available/2460875/Durham, NC-based dermatologist Dr. Brooke Jackson’s new book, “Skin Care for Runners”, is now available. The book is the definitive guide to healthy skin and nails for runners—and all athletes. In it, Dr. Jackson, also marathoner, offers tips and
- FDA Approves New Cheek Filler from Galdermahttps://practicaldermatology.com/news/fda-approves-new-cheek-filler-from-galderma/2460856/The U.S. Food and Drug Administration (FDA) approved Galderma’s Restylane Contour for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. Restylane Contour, a new hyaluronic acid (HA) dermal filler, is Galde
- New AKN Classification System May Improve Treatmenthttps://practicaldermatology.com/news/new-akn-classification-system-may-improve-treatment/2460852/A new classification system aims to improve the way that Acne Keloidalis Nuchae or AKN is treated. AKN can begin as tiny bumps on the back of the head, typically following a close haircut. However, due to a patient's genetic predisposition, these lesions become unremitt
- Can Blocking the Function of the CCR6 Chemokine Help Treat Psoriasis and Psoriatic Arthritis?https://practicaldermatology.com/news/can-blocking-the-function-of-the-ccr6-chemokine-help-treat-psoriasis-and-psoriatic-arthritis/2460825/A novel chemical blocker targeting chemokine proteins may significantly reduce skin and joint inflammation in psoriasis and psoriatic arthritis, according to a study in mice. Chemokines are small molecules with a critical role in the body’s response to inflammation and infection.
- Meet PDO Max's New Executive Hireshttps://practicaldermatology.com/news/meet-pdo-maxs-new-executive-hires/2460810/Dina BenDavid is the new Director of Training and Clinical Development at PDO Max. BenDavid is a board-certified nurse practitioner, holds both a Master's and Doctoral degrees, and is a professor of nursing and clinical trainer in medical aesthetics. She is founder and owner of
- Mederma Survey: America's Got Skin Insecuritieshttps://practicaldermatology.com/news/mederma-survey-skin-insecurities-have-major-impact-on-mental-health/2460797/One-third of Americans would not use their smart phone for a year if it meant they could have picture-perfect skin, according to a new survey from Mederma. That’s not all they would do for clear skin either, many would cancel Netflix for life eat only oatmeal for a year, giv
- FDA Accepts Amgen's sNDA for Otezla in Mild-to-Moderate PsOhttps://practicaldermatology.com/news/fda-accepts-amgens-snda-for-otezla-in-mild-to-moderate-pso/2460796/FDA has accepted for review the supplemental New Drug Application (sNDA) for Amgen's Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA has set a PDUFA action date of
- CorEvitas Enrolls 15,000 Patients in its Psoriasis and AD Registrieshttps://practicaldermatology.com/news/corevitas-enrolls-15000-patients-in-its-psoriasis-and-ad-registries/2460795/CorEvitas has enrolled more than 15,000 patients with immune-mediated skin diseases in the CorEvitas registries for moderate to severe psoriasis and atopic dermatitis (AD). This milestone was achieved by building on the company's real-world evidence program and dermatolog